DCV+ASV therapy was well tolerated and associated with lower rates of anemia and rash-related events. Disclosures: Kazuaki Chayama – Advisory Committees or Review Panels: Eisai, Mitsubishi Tanabe; Consulting: AbbVie, BMS; Grant/Research Support: Ajinomoto, Kyorin,
MSD, Eisai, Chugai, Torii, Tsumura, Teijin, Nippon Shinyaku, Toray, Dainippon Sumitomo, Mitsubishi Tanabe, BMS, Takeda, DAIICHI SANKYO, Nippon Sei- yaku, AstraZeneca, Nippon Silmitasertib ic50 Kayaku, Kowa; Speaking and Teaching: Ajinomoto, MSD, Astellas, AstraZeneca, Bayer, BMS, Chugai, DAIICHI SANKYO, Dainip- pon Sumitomo, Eisai, GlaxoSmithKline, Janssen, Takeda, Otsuka, Zeria, Meiji Seika, Mitsubishi Tanabe Yoshito Itoh – Grant/Research Support: MSD KK, Bristol-Meyers Squibb, Dain-ippon Sumitomo Pharm. Co., Ltd., Otsuka Pharmaceutical Co., Chugai Pharm Co., Ltd, Mitsubish iTanabe Pharm. Co.,Ltd., Daiichi Sankyo Pharm. Co.,Ltd., Takeda Pharm. Co.,Ltd., AstraZeneca K.K.:, Eisai Co.,Pharm.Ltd, FUJIFILM Medical Co.,Ltd. Hiroki Ishikawa – Employment: Bristol-Myers Squibb, Bristol-Myers Squibb Misti Linaberry – Employment: BMS Eric A. Hughes – Employment: Bristol-Myers Squibb Hiromitsu Kumada – Speaking and Teaching: Bristol-Myers
Squibb,Pharma International, MSD, Dainippon Sumitomo, Tanabe Mitsubishi, Ajinomoto The following people have nothing to disclose: Fumitaka Suzuki, Yoshiyuki www.selleckchem.com/products/chir-99021-ct99021-hcl.html Suzuki, Joji Toyota, Yoshiyasu Karino, Yoshiiku Kawakami, Shigetoshi Fujiyama, Takayoshi Ito, Etsuko Tamura, Tomoko Ueki Purpose:
People who inject drugs (PWID) are at the highest risk for chronic hepatitis C virus (HCV) infection, yet only a minority of PWID initiate treatment and even fewer complete a course of interferon-based therapy. Adults with chronic GT1 hepatitis C virus infection, including those with compensated cirrhosis, achieved high SVR12 rates in phase 2 and 3 trials of the interferon-free 3D regimen of ABT-450 (identified by Abb-Vie and Enanta, dosed with ritonavir, ABT-450/r), ombitasvir, selleck chemicals llc and dasabuvir, with or without ribavirin (RBV). We determined efficacy and safety of the 3D regimen ± RBV among HCV GT1-infected patients on chronic opioid substitution treatment (OST) with methadone or buprenorphine in phase 2/3 trials. Methods: Treatment-naïve, treatment-experienced, cirrhotic and non-cirrhotic patients included in this analysis were enrolled in phase 3 trials (SAPPHIRE-I or -II, PEARL-II, -III, or -IV, TUR-QUOISE-II) or phase 2 (AVIATOR, M14-103) trials of 3D±RBV and received at least one dose of study drug at the following or higher dosages: ABT-450 150mg once daily, ritonavir 100mg once daily, ombitasvir 25mg QD, and dasabuvir 250mg twice daily, with or without weight-based RBV. Patients with positive urine tests for illicit substances were excluded. Safety and efficacy were assessed for the subset of patients receiving stable OST.